StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research note published on Thursday morning. The firm issued a sell rating on the stock.

CTLT has been the subject of several other reports. Barclays lifted their price target on Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a report on Friday, June 28th. Royal Bank of Canada reissued a sector perform rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Finally, Stephens reissued an equal weight rating and set a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus target price of $55.65.

Catalent Price Performance

NYSE:CTLT opened at $59.59 on Thursday. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock’s 50 day moving average price is $56.66 and its two-hundred day moving average price is $56.03. The firm has a market capitalization of $10.78 billion, a price-to-earnings ratio of -9.77, a P/E/G ratio of 2.47 and a beta of 1.16. Catalent has a 12-month low of $31.80 and a 12-month high of $60.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, analysts anticipate that Catalent will post -0.17 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares in the company, valued at approximately $1,921,840.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Insiders sold 13,482 shares of company stock valued at $779,852 in the last three months. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Hedge funds and other institutional investors have recently modified their holdings of the business. Lindbrook Capital LLC increased its stake in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the last quarter. GAMMA Investing LLC bought a new position in shares of Catalent in the 4th quarter valued at $33,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalent in the 2nd quarter valued at $42,000. Rakuten Securities Inc. bought a new position in shares of Catalent in the 4th quarter valued at $46,000. Finally, Federated Hermes Inc. bought a new stake in Catalent during the 4th quarter worth $46,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.